Want to join the conversation?
Biotechnology company $AMGN announced detailed phase 2 results of erenumab drug that showed a significant reduction in monthly migraine days compared with placebo in patients with chronic migraine. This data will be presented at the 5th European Headache and Migraine Trust International Congress (EHMTIC) in Glasgow, Scotland.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.